Anto Bio (YC F25) LinkedIn · Jul 2026
Company post describing Anto’s multi-omic foundation-model approach, stating it has 1-10 employees, was founded in 2025, is headquartered in San Francisco, and has $625K in total funding with one prior round.
A Foundation Model for Microbial Communities.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Anto Biosciences (Anto Bio) is a YC Fall 2025, San Francisco-based frontier biology AI lab building multimodal foundation models for microbial communities so the gut microbiome becomes computable and can be used to predict drug toxicity/efficacy and optimize therapeutics.
Primary product
A multimodal foundation-model platform for microbial communities (the Darwin model series) that predicts drug–microbiome interactions, toxicity, and efficacy across populations.
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10 employees
Work style
Onsite
Industry
Biotechnology Research
Sub-industry
AI foundation models for microbiome and drug-discovery biotechnology
Offices
San Francisco, California, United States
Business model
B2B pharma R&D partnerships
enterprise research collaborations
Funding
Stage
Seed
Total raised
$500K
Latest round
Seed · Sep 2025
Latest amount
$500K
Sep 2025 · Y Combinator
People & investors
Work & culture
Mission-driven, research-first, high-ownership team; fully in-person in San Francisco; everyone on the team is a scientist and can code; fast iteration and publication-oriented.
Work style
Onsite
Product & market
Pricing
Not publicly disclosed; appears to be an enterprise B2B partnership/pilot model with pharma and biotech.
Differentiators
- —Quality-aware, goal-directed sparsification that reduces noisy microbiome data to the predictive signal
- —Multimodal foundation models built specifically for microbial communities
- —Prediction of drug toxicity and efficacy across diverse populations
- —Research-led lab with its own validation loops
- —Bridges computation, biology, pharmacology, and clinical outcomes
Technology
PyTorch
CUDA
torchrun
accelerate
multi-node training
reinforcement learning (RL)
supervised fine-tuning (SFT)
evaluation pipelines
quality-aware sparsification
tokenization
multimodal foundation models
metagenomics
causal modeling
multi-omics
Customers
pharmaceutical companies
biotechnology companies
pharma R&D teams
drug developers
Competitors
BioCorteX
Microbiotica
Vedanta Biosciences
Viome Life Sciences
Ginkgo Bioworks
Scale & contact
Estimated revenue
Estimated annual revenue about $180K (rough range $125K-$621K).
Estimated monthly visits
5.3K
Traffic estimate as of May 2026
Latest news
RRE Ventures LinkedIn · Jul 2026
RRE announced backing Anto Bio, describing the company as a frontier biology AI lab building multimodal foundation models for the gut microbiome.
Tekedia · Jun 2026
Tekedia Capital announced its investment and described Anto’s sparsification approach, Darwin model series, and drug-toxicity/efficacy predictions.
Forbes · Feb 2026
Arvid Gollwitzer wrote about MetaOmics-10T, sparsification, and making microbiome data usable for foundation-model pretraining.
Fondo · Feb 2026
Launch writeup summarizing Anto’s product, microbiome-focused foundation model, and pharma-use case.
Jobs and careers at Anto Biosciences
0 jobs at Anto Biosciences
No open positions
Check back later for new openings